NCT01942837 - Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2013

Primary Completion Date

December 31, 2021

Study Completion Date

September 30, 2022

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Enzalutamide

Enzalutamide, formerly known as MDV3100, is a rationally-designed second generation AR inhibitor which functions by blocking several steps in the AR signaling cascade. Enzalutamide competitively binds the AR with great potency. Additionally, enzalutamide inhibits nuclear translocation of activated AR and inhibits the association of activated AR with DNA.

Trial Locations (5)

98195

University of Washington Medical Center/Seattle Cancer Care Alliance, Seattle

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

02190

South Shore Hospital, Weymouth